Pertz Douglas A
Pertz Douglas A's purchase track record
How the stock did after each of Pertz Douglas A's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 12/18/2025 | VSTS | $172K | +7.1% | +86.9% | +10.7% |
| 5/8/2025 | VSTS | $432K | -17.2% | -16.8% | +18.6% |
| 5/24/2024 | VSTS | $914K | +15.3% | +34.1% | +12.5% |
| 5/3/2024 | VSTS | $1.10M | +34.0% | +43.2% | +11.7% |
| 12/14/2023 | VSTS | $201K | -4.4% | -37.1% | +15.1% |
| 6/9/2023 | AAP | $402K | +2.0% | -10.8% | +7.1% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
AAP sets date for Q3 2026 earnings release. Advance Auto Parts has scheduled the release of its third‑quarter 2026 earnings and the accompanying conference call. The company gave the specific date but no financial details yet. This timing lets investors plan for the upcoming results discussion. The announcement comes as the stock trades near its recent support level.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
Brink's Gets CMA Approval for NCR Atleos Deal Remedy. Brink's received acceptance in principle from the UK's CMA regarding a proposed remedy for its pending acquisition of NCR Atleos. The company also reported Q2 2026 results and confirmed that a potential sale of UK assets will not impact expected $200M in annual synergies. This regulatory progress is a key step in finalizing the transaction.
Transaction History
| VSTS | ▲ Buy | Grant | 18,253 | $0 | 2/18/2026 | View on chart |
| VSTS | ▲ Buy | Open Market | 15,000 | $103K | 12/19/2025 | View on chart |
| VSTS | ▲ Buy | Open Market | 10,000 | $69K | 12/18/2025 | View on chart |
| VSTS | ▲ Buy | Open Market | 70,000 | $432K | 5/8/2025 | View on chart |
| AAP | ▲ Buy | Grant | 96 | $3K | 4/25/2025 | View on chart |
| VSTS | ▲ Buy | Grant | 71 | $0 | 3/18/2025 | View on chart |
| VSTS | ▲ Buy | Grant | 8,734 | $0 | 1/28/2025 | View on chart |
| AAP | ▲ Buy | Grant | 65 | $3K | 1/24/2025 | View on chart |
| VSTS | ▲ Buy | Grant | 45 | $0 | 1/6/2025 | View on chart |
| AAP | ▲ Buy | Grant | 85 | $3K | 10/25/2024 | View on chart |
| VSTS | ▲ Buy | Grant | 50 | $0 | 10/3/2024 | View on chart |
| AAP | ▲ Buy | Grant | 51 | $3K | 7/26/2024 | View on chart |
| VSTS | ▲ Buy | Grant | 63 | $0 | 7/2/2024 | View on chart |
| AAP | ▲ Buy | Grant | 2,530 | $165K | 6/4/2024 | View on chart |
| VSTS | ▲ Buy | Open Market | 22,442 | $261K | 5/28/2024 | View on chart |
| VSTS | ▲ Buy | Open Market | 54,468 | $653K | 5/24/2024 | View on chart |
| VSTS | ▲ Buy | Open Market | 110,000 | $1.1M | 5/3/2024 | View on chart |
| AAP | ▲ Buy | Grant | 33 | $2K | 4/26/2024 | View on chart |
| VSTS | ▲ Buy | Grant | 39 | $0 | 4/4/2024 | View on chart |
| VSTS | ▲ Buy | Grant | 7,377 | $0 | 2/16/2024 | View on chart |
| AAP | ▲ Buy | Grant | 37 | $2K | 1/26/2024 | View on chart |
| VSTS | ▲ Buy | Grant | 23 | $0 | 1/4/2024 | View on chart |
| VSTS | ▲ Buy | Open Market | 5,120 | $100K | 12/15/2023 | View on chart |
| VSTS | ▲ Buy | Open Market | 5,250 | $100K | 12/14/2023 | View on chart |
| AAP | ▲ Buy | Grant | 49 | $2K | 10/27/2023 | View on chart |
| VSTS | ▲ Buy | Grant | 2,744 | $0 | 10/2/2023 | View on chart |
| VSTS | ▲ Buy | Grant | 10,583 | $0 | 10/2/2023 | View on chart |
| AAP | ▲ Buy | Grant | 33 | $2K | 7/28/2023 | View on chart |
| AAP | ▲ Buy | Grant | 2,467 | $165K | 6/12/2023 | View on chart |
| AAP | ▲ Buy | Open Market | 4,575 | $302K | 6/12/2023 | View on chart |
| AAP | ▲ Buy | Grant | 1,757 | $118K | 6/12/2023 | View on chart |
| AAP | ▲ Buy | Open Market | 1,570 | $100K | 6/9/2023 | View on chart |
| AAP | ▲ Buy | Grant | 65 | $8K | 4/28/2023 | View on chart |
| BCO | ▼ Sell | Tax Withholding | 11,818 | $717K | 3/17/2023 | View on chart |
| BCO | ▲ Buy | Grant | 15,306 | $0 | 3/3/2023 | View on chart |
| BCO | ▼ Sell | Tax Withholding | 924 | $61K | 3/1/2023 | View on chart |
| BCO | ▲ Buy | Option Exercise | 215,382 | $11.4M | 2/17/2023 | View on chart |
| BCO | ▼ Sell | Tax Withholding | 177,633 | $11.4M | 2/17/2023 | View on chart |
| BCO | ▼ Sell | Tax Withholding | 33,822 | $2.1M | 2/16/2023 | View on chart |
| BCO | ▲ Buy | Grant | 137,746 | $0 | 2/16/2023 | View on chart |
| AAP | ▲ Buy | Grant | 53 | $8K | 1/3/2023 | View on chart |
| BCO | ▼ Sell | Tax Withholding | 11,314 | $671K | 12/3/2022 | View on chart |
| AAP | ▲ Buy | Grant | 51 | $8K | 9/30/2022 | View on chart |
| AAP | ▲ Buy | Grant | 46 | $8K | 7/1/2022 | View on chart |
| BCO | ▲ Buy | Option Exercise | 400,000 | $11.9M | 6/8/2022 | View on chart |
| BCO | ▼ Sell | Tax Withholding | 109,326 | $6.8M | 6/8/2022 | View on chart |
| BCO | ▼ Sell | Tax Withholding | 81,447 | $5.0M | 6/8/2022 | View on chart |
| BCO | ▼ Sell | Tax Withholding | 83,696 | $5.2M | 6/8/2022 | View on chart |
| AAP | ▲ Buy | Grant | 855 | $165K | 5/30/2022 | View on chart |
| AAP | ▲ Buy | Grant | 32 | $7K | 4/1/2022 | View on chart |
| BCO | ▲ Buy | Grant | 30,031 | $0 | 3/17/2022 | View on chart |
| BCO | ▲ Buy | Grant | 7,044 | $0 | 3/1/2022 | View on chart |
| BCO | ▲ Buy | Grant | 35,533 | $0 | 2/17/2022 | View on chart |
| BCO | ▼ Sell | Tax Withholding | 11,826 | $819K | 2/17/2022 | View on chart |
| AAP | ▲ Buy | Grant | 18 | $4K | 1/3/2022 | View on chart |
| AAP | ▲ Buy | Grant | 21 | $4K | 10/1/2021 | View on chart |
| AAP | ▲ Buy | Grant | 5 | $876 | 4/5/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
Vestis Names New CFO, Could Alter Turnaround Strategy
Vestis Corporation has appointed a new chief financial officer, a move that may change the company’s approach to its turnaround plan. The hire signals a possible shift in how the firm will manage costs and growth, which could affect its financial outlook. The stock is trading near a key support level of $12.78, and analysts expect a target of $13.00 on average. This development is noteworthy for stakeholders watching the company’s recovery path.
Vestis Names New CFO, Could Alter Turnaround Strategy. Vestis Corporation has appointed a new chief financial officer, a move that may change the company’s approach to its turnaround plan. The hire signals a possible shift in how the firm will manage costs and growth, which could affect its financial outlook. The stock is trading near a key support level of $12.78, and analysts expect a target of $13.00 on average. This development is noteworthy for stakeholders watching the company’s recovery path.